Glatiramer acetate
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Copaxone)
 | This article is a stub. |
Copaxone or glatopa, and glatiramer, its generic form, is glatiramer acetate (copaxone), an FDA-approved immunomodulator licensed to reduce relapses in patients with multiple sclerosis.[1]
ME/CFS[edit | edit source]
Ron Davis of the Open Medicine Foundation reports that when the nanoneedle electrical impedance test on ME/CFS cells was used, Copaxone made the cells respond in the same way as healthy cells did, suggesting it is a potential treatment for ME/CFS.[2]
Notable studies[edit | edit source]
- 2023, Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[3] - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Copaxone - drugs.com
References[edit | edit source]
- ↑ "Copaxone: Uses, Dosage, Side Effects". Drugs.com. Retrieved April 30, 2019.
- ↑ Davis, Ron (September 2019). "Dr. Ron Davis Presents on ME/CFS Research Activities at Stanford at Inaugural Harvard Symposium". Retrieved September 8, 2019.
- ↑ Jensen, Michael Anthony; Dafoe, Miranda Lee; Wilhelmy, Julie; Cervantes, Layla; Okumu, Anna N.; Kipp, Lucas; Nemat-Gorgani, Mohsen; Davis, Ronald Wayne (November 27, 2023). "Catalytic Antibodies May Contribute to Demyelination in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Biochemistry. doi:10.1021/acs.biochem.3c00433. ISSN 1520-4995. PMID 38011893.
